Genomic valley biotech Limited has filed its annual regulatory declaration under SEBI's takeover regulations, confirming compliance with substantial acquisition norms for the financial year ended 31st March 2026. The declaration was submitted to BSE Limited and the company's audit committee as part of mandatory regulatory requirements.

SEBI Regulatory Declaration

Promoter Yogesh Agrawal filed the declaration under Regulation 31(4) of SEBI (Substantial Acquisition of shares & Takeover) Regulations, 2011 on 1st April, 2026. The declaration confirms that no encumbrance was made directly or indirectly during the financial year by the promoters, promoter group members, or persons acting in concert.

Company Information and Contact Details

Genomic Valley Biotech Limited operates from its registered address at 4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil Bahadurgarh, District Jhajjar, Haryana, India - 124 507. The company maintains corporate communication through genomicvalley@gmail.com and operates its website at www.genomicvalley.com .

Promoter Group Structure

The company's promoter group consists of three members across different categories as of March 31, 2026. The declaration was made on behalf of all promoters, promoter group members, and persons acting in concert with the company.

Regulatory Compliance

The declaration represents the company's adherence to SEBI's substantial acquisition and takeover regulations, which require periodic disclosures from promoters and associated entities. The filing confirms that no encumbrance activities occurred during the financial year, maintaining transparency in shareholding patterns and promoter activities. The document was digitally signed by Yogesh Agrawal and submitted to both BSE Limited and the company's audit committee as per regulatory requirements.

Genomic Valley Biotech Limited announced its financial results for the quarter and nine months ended December 31, 2025, alongside significant board changes. The company's Board of Directors convened on January 15, 2026, to approve the unaudited financial results and address directorship matters.

Q3FY26 Financial Performance

The company's third quarter performance showed mixed results compared to previous periods. Key financial metrics for the quarter demonstrate the company's current operational status.

The quarterly results indicate a significant decline in revenue from operations, falling from ₹22.01 lakh in Q3FY25 to ₹5.00 lakh in Q3FY26. Despite lower revenues, the company maintained profitability with a net profit of ₹1.05 lakh, though substantially reduced from the previous year's ₹15.54 lakh.

Nine-Month Performance Analysis

The nine-month period ending December 31, 2025, reflects similar trends in the company's financial trajectory.

For the nine-month period, total revenue decreased to ₹23.00 lakh from ₹58.81 lakh in the corresponding previous period. The company recorded a net profit of ₹3.85 lakh compared to ₹43.05 lakh in the same period last year.

Board Changes and Corporate Governance

The Board meeting also addressed significant governance matters, particularly regarding directorship changes.

Mr. Ashok Kumar ceased to be a Director and member of all committees of the company with immediate effect from January 15, 2026. The cessation occurred due to non-completion of KYC requirements as mandated under Section 167 of the Companies Act, 2013.

Operational Highlights

The company's operational structure remained consistent with previous periods. Key operational aspects include:

The financial results were reviewed by the Audit Committee and approved by the Board of Directors. Statutory auditors ANDROS & CO. Chartered Accountants conducted a limited review of the financial results, confirming compliance with applicable Indian Accounting Standards and SEBI regulations. The Board meeting commenced at 5:00 PM and concluded at 5:30 PM on January 15, 2026.